State coverage
Oregon Medicaid and GLP-1 coverage
Medicaid, for obesity: Other diagnoses only. The conditions and the appeal deadline are in the summary below.
At a glance
- Medicaid, for obesity
- Excludes these drugs from its Prioritized List of Health Services entirely, not from a drug list.
- Appeal deadline
- 60 days from the date on the notice, to your CCO or to OHA. 10 days from the effective date to keep a service running source
- Date read
- September 2026
Oregon ends up in the same place as several other states, but it gets there in a way that changes what you can do about it.
The Oregon Health Plan does not start by deciding drug by drug. It ranks health services on a Prioritized List, pays down to a cutoff, and covers what sits above it. Obesity has its own line, and the guideline attached to that line says what treating it means: intensive counseling on food and exercise. Not medication.
Then it says so plainly: drugs and devices for obesity are not meant to be on that line, or on any other line. Nothing on the list means nothing the plan buys. So the door closed a level above the drug list, which is why arguing about the drug list will not open it.
You can still get these drugs for something other than obesity, and Oregon says exactly where that line falls for each one. If you are under 21, the state reviews it case by case instead.
What we could verify for Oregon
Oregon settles what treating obesity means before it decides what to pay for. Guideline Note 5, attached to Line 317, states: "Medical treatment of overweight (with known cardiovascular risk factors) and obesity in adults is limited to intensive counseling on nutrition and physical activity, provided by health care professionals." It defines intensive counseling as "face-to-face contact more than monthly", includes it for six months, and allows a further six "as long as there is evidence of continued weight loss or improvement in cardiovascular risk factors based on the intervention."
Oregon Health Authority, Health Evidence Review Commission, Prioritized List of Health Services — Guideline Notes, effective February 2026 · source
The same note keeps the drugs off the list entirely, rather than off a formulary: "Pharmacological treatments and devices (e.g., gastric balloons, duodenal jejunal bypass liners, and vagus nerve blocking devices) for obesity are not intended to be included as services on this line or any other line on the Prioritized List." That is a decision about which services the plan buys at all, taken one level above any drug list.
Oregon Health Authority, Health Evidence Review Commission, Prioritized List of Health Services — Guideline Notes, effective February 2026 · source
That decision lives in the Prioritized List itself, which is dated on its face: the edition in force is headed "FEBRUARY 1, 2026" and footed "Including errata and revisions as of 8-13-2026".
Oregon Health Authority, Health Evidence Review Commission, Prioritized List of Health Services, effective February 2026 · source
The pharmacy criteria draw the line drug by drug, in a note rather than a table: "Semaglutide is not currently covered for adults who do not have established cardiovascular disease, metabolic dysfunction-associated steatohepatitis (MASH), or type 2 diabetes. Tirzepatide is not currently covered for adults who do not have established obstructive sleep apnea or type 2 diabetes. Liraglutide is not covered for adults who do not have type 2 diabetes or MASH." Authorization runs "Up to 6 months" with "Renewal up to 12 months".
Oregon Health Authority, Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria Guide, effective July 2026 · source
Under 21, someone looks at your case instead of the list deciding it. Among the stated goals of the weight management criteria is to "Allow case-by-case review for members covered under the EPSDT program", alongside a goal to "Recommend use of GLP-1 receptor agonists only for FDA-approved indications supported by the evidence." The same section requires prior authorization for "All drugs used for weight management."
Oregon Health Authority, Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria Guide, effective July 2026 · source
You get 60 days either way, counted from the date printed on your letter, not from when you opened it. For coordinated care members, "Your CCO must receive your appeal within 60 days from the date on the Notice of Adverse Benefit Determination." For a state denial the hearing form must reach the agency within "60 calendar days of the date on the Notice of Denial from OHA, or 120 calendar days of the date of the Notice of Appeal Resolution". Keeping a service running is a much shorter and differently anchored clock: ask "within 10 days of the effective date on the notice from the CCO or OHA."
Oregon Health Authority, Oregon Health Plan — Appeals and Hearings · source
Oregon is one of 33 states whose Medicaid gives the same answer: weight loss excluded; heart, liver or sleep apnea can qualify. Oregon Medicaid's rule doesn't reach a job-based plan or Medicare. If you have one of those, read employer plans or Medicare Part D instead, and compare Oregon with the rest in the coverage matrix.
Regional insurers that sell plans in Oregon and have their own page here, quoted from their own policy documents: Kaiser Permanente Northwest and Regence. The national insurers are on the insurance index.
If you work for the State of Oregon
State employees aren't on Medicaid, so the answer above isn't yours. Your plan is the one the state buys for its workers: Public Employees' Benefit Board (PEBB). Its pharmacy benefit runs through each medical plan: Providence Health Plan (Statewide) or Moda Health (Synergy).
Weight loss drugs excluded; WW program instead
Oregon's PEBB medical plans exclude drugs used for weight loss in 2026. What you get instead is a WeightWatchers (WW) weight management benefit and, for morbid obesity, bariatric surgery with prior authorization.
The 2026 Statewide plan handbook says "In addition to the limitations and exclusions set forth in this Member Handbook, Prescription Drug Exclusions are as follows:" and lists "Drugs used for weight loss;"
Providence Health Plan, PEBB 2026 Statewide Handbook (Member Handbook, Statewide Plan), effective January 2026 · source
The 2026 Moda Synergy handbook's pharmacy exclusions say "these medications and supplies are not covered:" and list "Weight Loss Medications."
Moda Health, 2026 Oregon Group Medical Plan, Public Employees' Benefit Board, Synergy Full-Time handbook, effective January 2026 · source
Statewide plan members use their ID card to "Call Weight Watchers® to access your weight management benefit."
Providence Health Plan, PEBB 2026 Statewide Handbook (Member Handbook, Statewide Plan), effective January 2026 · source
Bariatric surgery stays covered: "Coverage is provided In-Network for Medically Necessary bariatric surgery procedures for the treatment of morbid obesity in adults" and "Prior Authorization is required for certain bariatric surgery Covered Services."
Providence Health Plan, PEBB 2026 Statewide Handbook (Member Handbook, Statewide Plan), effective January 2026 · source
If the appeal fails, or you cannot wait
Oregon Medicaid excludes weight loss but can still approve these drugs for another approved use, set out in the facts above. If none of those applies to you, cash-pay telehealth is the fallback: you pay the whole cost yourself, with no Medicaid help.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
| Company | What we found on its own site |
|---|---|
| PartnerShedRxCheck availability | Injections plus needle-free drops and lozenges. You see a price only after the questionnaire, and the oral forms aren't sold in sixteen states. |
| PartnerHealthRXCheck availability | Compounded semaglutide at $133 a month on a three-month plan ($99 on twelve), tirzepatide from $209 ($179 on twelve). Its member reviews are labeled illustrative composites, not real patients. |
| PartnerMEDGmCheck availability | GLP-1 injections from $179 and tablets from $249. Brand options are a membership plus the drug's own cost: $99 for Zepbound or Wegovy, $171 for Ozempic. It discloses AI content and actor imagery. |
| PartnerBodybuilding Health+Check availability | Compounded tirzepatide at $174.67 to $209 a month, lower the more months you buy at once; semaglutide is tiered the same way. Operated by Dynamo Group LLC. |
| PartnerStrut HealthCheck availability | A telehealth storefront where weight loss is one of six categories. No GLP-1 price is published on the page our link opens. |
| PartnerRxSpan MDCheck availability | Multi-category telehealth that promises transparent pricing, then publishes no GLP-1 price on the page our link opens. |
All 21 companies, with what we found on each →
Prices in those notes were read from each company's own site in September 2026, and they change often. Check the current number before you buy.
Where this comes from
- Oregon Health Authority, Health Evidence Review Commission, Prioritized List of Health Services — Guideline Notes, effective February 2026 — www.oregon.gov/oha/HPA/DSI-HERC/PrioritizedList/2-1-2026GL.txt
- Oregon Health Authority, Health Evidence Review Commission, Prioritized List of Health Services, effective February 2026 — www.oregon.gov/oha/HPA/DSI-HERC/PrioritizedList/2-1-2026%20Prioritized%2
- Oregon Health Authority, Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria Guide, effective July 2026 — www.oregon.gov/oha/HSD/OHP/Tools/Oregon%20Medicaid%20PA%20Criteria%20Gui
- Oregon Health Authority, Oregon Health Plan — Appeals and Hearings — www.oregon.gov/oha/HSD/OHP/Pages/Appeals-Hearings.aspx